Journal
ACTA PHARMACEUTICA SINICA B
Volume 10, Issue 9, Pages 1589-1600Publisher
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2020.04.012
Keywords
Antibody drug conjugates; Antibody; Cytotoxic agents; Linker; Clinical application
Categories
Funding
- College of Pharmacy at The Ohio State University
Ask authors/readers for more resources
Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris (R)) for relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, gemtuzumab ozogamicin (Mylotarg (R)) for acute myeloid leukemia, ado-trastuzumab emtansine (Kadcyla (R)) for HER2-positive metastatic breast cancer, inotuzumab ozogamicin (Besponsa (R)) and most recently polatuzumab vedotin-piiq (Polivy (R)) for B cell malignancies. More than eighty ADCs have been investigated in different clinical stages from approximately six hundred clinical trials to date. This review summarizes the key elements of ADCs and highlights recent advances of ADCs, as well as important lessons learned from clinical data, and future directions. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available